“…While lower levels of constitutively produced NO are involved in the regulation of mitochondrial activity by competing with oxygen at the level of complex IV of the respiratory chain (Erusalimsky & Moncada, 2007), higher concentrations of NO have been shown to persistently inhibit mitochondrial function by nitrosylation of electron chain complexes, in particular complex I (Clementi et al, 1998), and to cause DNA damage (Delaney et al, 1993;deRojas-Walker et al, 1995). Endothelial dysfunction is apparent in conditions such as hypertension, heart failure, coronary artery disease, and atherosclerosis (Cai & Harrison, 2000;Vanhoutte, 2009;de Berrazueta et al, 2010). During these pathophysiological conditions, eNOS-dependent conversion of L-arginine to NO is impaired and thus NO bioavailability is reduced, concurrent with decrease in NO-mediated vasorelaxation (Shimokawa et al, 1991;Pou et al, 1992;Harrison, 1997;Wilcox et al, 1997).…”